HIV

July 13, 2020

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

July 09, 2020

Both trial sub-analyses will be presented at the virtual 23rd International AIDS Conference.

July 08, 2020

Survey results on PrEP access and utilization during COVID-19 shelter-in-place orders presented at the 23rd International AIDS Conference.

July 03, 2020

Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.

June 12, 2020

Officials with the FDA have approved dolutegravir (Tivicay PD, ViiV Healthcare) dispersible tablets for oral suspension for children who are at least 4 weeks of age and weigh at least 3 kg.

June 08, 2020

Virtual care takes center stage amid the pandemic.

May 20, 2020

A new review in JAMA Pediatrics looks at the current status of PrEP uptake among adolescents aged 13 to 19 years who are at risk for HIV. 

April 30, 2020

In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.

March 23, 2020

Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.

March 10, 2020

At the 2020 Conference on Retroviruses and Opportunistic Infections (CROI), longer-term study results on emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for HIV PrEP were presented.